We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Studies of Suppressor Gene Advance Understanding of Metastasis

By LabMedica International staff writers
Posted on 17 Jan 2016
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer and these findings may lay the foundation for new colorectal cancer treatments.

Cancer deaths attributed to colorectal cancer are mainly due to tumor recurrence and metastasis to other organs and excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the USA. More...
It is estimated that the lifetime risk of developing colorectal cancer is about 1 in 20.

Scientists at the University of Missouri (Columbia, MO, USA) used cancer cell models, mouse models and human biopsy samples and by using different molecular methods, the team found that the Sprouty2 (SPRY2) gene functions differently in colorectal cancer (CRC) than in other types of cancers. Sprouty (SPRY) is an intracellular regulator of receptor tyrosine kinase signaling involved in growth, differentiation and tumorigenesis. Four family members of SPRY (SPRY1–4) have been identified. SPRY2 appears to be ubiquitously expressed, whereas other family members show organ and tissue specificity.

Among the various techniques used, 3′UTR reporter assays were performed and the luminescence was measured by a luminometer (Turner Biosystems Inc.; Sunnyvale, CA, USA) confocal microscopy using a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystems Inc.; Buffalo Grove, IL, USA) was performed; and formalin-fixed, paraffin-embedded human colorectal cancer (CRC) tissue microarray (Biomax; Rockville, MD, USA) was utilized for V-Akt Murine Thymoma Viral Oncogene Homolog 2(AKT2) and E-cadherin (CDH1) immunostaining.

The team found that in colorectal cancer, SPRY2 may increase the metastatic ability of cancer cells instead of suppress it. SPRY1 and SPRY2 messenger ribonucleic acid (mRNA) transcripts were significantly upregulated in human CRC. Suppression of SPRY2 repressed AKT2 and epithelial-mesenchymal transition inducing transcription factors and significantly increased E-cadherin expression. Concurrent downregulation of SPRY1 and SPRY2 also increased E-cadherin and suppressed mesenchymal markers in colon cancer cells. By confocal microscopy, they demonstrated redistribution of E-cadherin to plasma membrane in colon cancer cells transfected with miR-194.

Sharad Khare, PhD, an associate professor and senior author of the study said, “The gene known as Sprouty2 has previously been shown to protect against metastasis, or the spreading of cancer to other parts of the body, in breast, prostate and liver cancer. However, our recent molecular studies found that this gene may actually help promote metastasis instead of suppress it. This finding is a very significant step in our understanding of metastasis in colorectal cancer, but it's important to note that we believe this phenomenon may occur in only a subset of colorectal cancer patients.” The study was published originally in advance of print, online on October 5, 2015, in the journal Oncogene.

Related Links:

University of Missouri
Turner Biosystems Inc. 
Leica Microsystems Inc.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.